F097 Dermatologic Care for the Leukemia and Lymphoma Patient
DESCRIPTION
There have been tremendous advances in treatment of hematologic cancers, including targeted therapies, immunotherapies, cellular therapies (CAR-T) and advances in HCT. These treatments may lead to significant cutaneous toxicities that dermatologists encounter. This session will prepare you to recognize novel therapies for hematologic cancers in order to identify and assess associated drug-related cutaneous side effects. We will categorize common rashes that develop in leukemia and lymphoma patients, including drug toxicities and infectious complications. We will also review the associated histopathology.
LEARNING OBJECTIVES
Recognize novel therapies for leukemia and lymphoma manage associated skin toxicities.
Review dermatopathology of toxicities in patients with leukemia and lymphoma.
Outline dermatologic infections experienced by patients with leukemia and lymphoma.
SCHEDULE
9:00 AM
Leukemia and Lymphoma Patient Dermatopathology
Anisha Patel, MD, FAAD
9:25 AM
Leukemia and Lymphoma Patient Dermatopathology Q&A
Anisha Patel, MD, FAAD
9:30 AM
Derm Toxicities in the Lymphoma Patient
Timothy Dang, MD, FAAD
9:55 AM
Derm Toxicities in the Lymphoma Patient Q&A
Timothy Dang, MD, FAAD
10:00 AM
Derm Toxicities in the Leukemia Patient
Alina Markova, MD, FAAD
10:25 AM
Derm Toxicities in the Leukemia Patient Q&A
Alina Markova, MD, FAAD
10:30 AM
Dermatologic infections in the Leukemia and Lymphoma patient
Bernice Kwong, MD, FAAD
10:55 AM
Dermatologic infections in the Leukemia and Lymphoma patient Q&A
Bernice Kwong, MD, FAAD
DIRECTOR
Alina Markova, MD, FAAD
SPEAKERS
Timothy Dang, MD, FAAD
Bernice Kwong, MD, FAAD
Anisha Patel, MD, FAAD
HANDOUTS
DISCLOSURES
Timothy Dang, MD, FAAD
No financial relationships exist with ineligible companies.
Bernice Kwong, MD, FAAD
Happy 2nd Birthday, Inc – Consultant(Fees), Consultant(No Compensation Received); Novartis – Consultant(Fees); Novocure – Investigator(No Compensation Received); OncoDerm LLC – Consultant(No Compensation Received);
Alina Markova, MD, FAAD
Amryt Pharma – Investigator(Grants/Research Funding); AstraZeneca – Consultant (1099 relationship)(Fees); Incyte Corporation – Investigator(Grants/Research Funding); Janssen Biotech – Investigator(Grants/Research Funding); Kintara Therapeutics, Inc. – Investigator(Grants/Research Funding); National Institutes of Health – Investigator(Grants/Research Funding); Novartis – Investigator(Grants/Research Funding); Novocure – Investigator(Grants/Research Funding); Sanofi Genzyme – Advisory Board(Honoraria); Treeline – Consultant (1099 relationship)(Honoraria); UpToDate – Other(Patent royalties or other compensation for Intellectual Property Rights);
Anisha Patel, MD, FAAD
Astellas Pharma US, Inc – Consultant (1099 relationship)(Fees); Asymmetric Therapeutics, LLC – Consultant (1099 relationship)(Fees); Deciphera Pharmaceuticals, Inc. – Consultant (1099 relationship)(Fees); EMD Serono – Advisory Board(Fees); Erasca – Consultant (1099 relationship)(Fees); FBIO Acquisition Corp LXI – Consultant (1099 relationship)(Stock); Hoth Therapeutics – Investigator(Grants/Research Funding); IDEOlogy Health – Consultant (1099 relationship)(Fees); Janssen Scientific Affairs, LLC – Consultant (1099 relationship)(Fees); Lutris – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Revolution Medicines – Advisory Board(Fees); Roche Pharma – Consultant (1099 relationship)(Fees); SynOx Therapeutics – Consultant (1099 relationship)(Fees); UpToDate, Inc – Other(Patent royalties or other compensation for Intellectual Property Rights);